Furthermore, obesity and CKD presence appear to enhance responsiveness, as seen in the FLOW [12] and STEP trials [13], where semaglutide provided substantial benefit in reducing CV death, HF events, and NT-proBNP levels in patients with these comorbidities. The gene discussed is NPPB; the disease is obesity due to melanocortin 4 receptor deficiency.